Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Must have provided written informed consent~2. Definite or probable PBC diagnosis as demonstrated by the presence of at least 2 of the following 3 diagnostic factors:~   * History of elevated ALP levels for at least 6 months prior to Day 0 (randomization visit)~  * Positive Anti-Mitochondrial Antibodies (AMA) titers (\> 1/40 on immunofluorescence or M2 positive by enzyme-linked immunosorbent assay (ELISA) or positive PBC-specific antinuclear antibodies~  * Liver biopsy consistent with PBC~3. ALP \>= 1.67x upper limit of normal (ULN)~4. Taking UDCA for at least 12 months (stable dose for ≥ 6 months) prior to screening visit~5. Contraception: Females participating in this study must be of non-childbearing potential or must be using highly efficient contraception for the full duration of the study and for 1 month after the end of treatment.~Exclusion Criteria:~1. History or presence of other concomitant liver diseases~2. Screening creatine phosphokinase (CPK) \> upper limits of normal (ULN)~3. Screening alanine transaminase (ALT) or aspartate aminotransferase (AST) \> 5 ULN~4. Screening total bilirubin \> 2 ULN~5. Screening serum creatinine \> 1.5 mg/dl~6. Significant renal disease, including nephritic syndrome, chronic kidney disease (defined as patients with markers of kidney damage or estimated glomerular filtration rate \[eGFR\] of less than 60 mL/min/1.73 m\^2).~7. Patients with moderate or severe hepatic impairment (defined as Child-Pugh B/C)~8. Platelet count \<150 X 10\^3/microliter~9. Albumin \<3.5 g/dL~10. Presence of clinical complications of PBC or clinically significant hepatic decompensation~11. If female: known pregnancy, or has a positive urine pregnancy test (confirmed by a positive serum pregnancy test), or lactating~12. Known history of human immunodeficiency virus (HIV) infection~13. Medical conditions that may cause non-hepatic increases in ALP (e.g., Paget's disease)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
- Elafibranor 80 mg (Type: ACTIVE_COMPARATOR): Study subjects will take two tablets per day orally before breakfast with a glass of water each morning
- Elafibranor 120 mg (Type: ACTIVE_COMPARATOR): Study subjects will take two tablets per day orally before breakfast with a glass of water each morning

Based on this trial design, predict the completion outcome and termination type (if applicable).